https://eureka.patsnap.com/resources/blog/rd-blog/engineered-bacteria-as-therapeutics-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Microbiome Therapeutics
Engineered bacteria as therapeutics: what the patents show about who leads and what remains open
  • Filing peaked in 2020 at 123 records, then eased through 2021-2024 — filings fell 56% from 103 in 2021 to 45 in 2024, the last year publication lag lets us call complete.
  • Half the field sits with five assignees: the top 5 hold 565 of 1,128 records in scope (50.1%), with a long tail of single- and few-filing entrants behind them.
  • Claims cluster tightly on microbial engineering itself: C12N covers 82.9% of records, while measurement and analytical classes (C12Q, G01N) each sit under 7%.
Get a prior-art report on your approach
1,128
Published Records
50%
Top-5 Share of All Records
-56%
Filing Growth 2021→2024
US
Leading Jurisdiction

Filing growth compares 2021 (103 records) with 2024 (45) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 1,128 records in scope (CR5), not by the ranked leaders only.

Published byPatsnap Research··6 min readSourced from Patsnap Eureka
Overview

What this landscape covers

Engineered bacteria as therapeutics spans strains built to secrete a payload, persist in a host niche, or shut themselves down on command. The search set pulls records that combine an engineered-bacterium or biocontainment claim with a functional control mechanism — payload secretion, kill-switch reliability, horizontal transfer risk, colonization persistence, inducible expression, or containment efficiency. That pairing is deliberate: it separates strains built as delivery platforms from the broader genetic-engineering literature that never addresses safety or control.

The scope runs from 2015 through the 2026-07-31 cut-off, covering 1,128 published records. Because publication typically lags filing by around 18 months, the most recent one to two years understate actual filing activity and should be read as still filling in.

Filing activity and technology composition, 2015-2026
  1. 1SYNLOGIC OPERATING CO INC160
  2. 2MASSACHUSETTS INST OF TECH159
  3. 3THE BROAD INST INC139
  4. 4ACTYM THERAPEUTICS INC63
  5. 5DUKE UNIV44
  6. 6YEDA RES & DEV CO LTD29
  7. 7HERVANA29
  8. 8WASHINGTON UNIV IN SAINT LOUIS24
  9. 9NATIONAL UNIVERSITY OF SINGAPORE22
  10. 10THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA20
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Engineered Bacteria as Therapeutics covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP

Let an AI agent run this analysis on your own technology

Pick a task. Every answer cites the patents behind it.

10,000 free credits to start
The Data

Filing trend and technology composition

Two views of the same 1,128 records: how filing activity has moved year over year, and which IPC subclasses carry the claims.

Filing trend, 2017-2026

Filings rose to a peak of 123 in 2020, then declined; the 2021-to-2024 span (the last year treatable as complete) fell 56%, from 103 to 45. Years after 2024 are still incomplete due to publication lag and should not be read as a continuation of that decline.

Filing trend, 2017-2026038751131506720172018201912320202021202220232024202532026Most recent year is partial — publication lag means later filings are not yet visible.

IPC subclass composition

C12N (microorganisms and genetic engineering) appears on 82.9% of records and A61K (medicinal preparations) on 55.1%, confirming the corpus is dominated by strain construction and formulation claims rather than diagnostic or analytical work — C12Q and G01N each sit below 7%. Because records carry multiple classes, these shares sum to well over 100%.

IPC subclass compositionC12N · Microorganisms & genetic engin…93582.9%A61K · Medicinal preparations62155.1%C07K · Peptides & proteins37233.0%A61P · Therapeutic activity of compou…20818.4%C12P · Fermentation & enzymatic synth…20217.9%C12R · Microorganisms (index)897.9%C12Q · Measuring & testing involving …716.3%G01N · Material analysis & testing454.0%Other22319.8%

Shares are the percentage of the 1,128 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.

Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Engineered Bacteria as Therapeutics covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.

Go deeper on Engineered Bacteria as Therapeutics with Eureka

This page is one run against one query. Ask Eureka your own question about engineered bacteria as therapeutics and every answer comes back with the patent numbers behind it.

Try Eureka
Key Patents

Representative and most-cited filings

Representative Filing
US20190010506A12019-01-10

US20190010506A1 — Bacteria engineered to treat metabolic diseases

SYNLOGIC OPERATING COMPANY, INC.

Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of attenuating metabolic diseases are disclosed.Filed by Synlogic Operating Company, published 2019-01-10 — illustrative of the strain-plus-pharmaceutical-composition claim structure that recurs across the leading assignees in this dataset.

US20190010506A1 — patent drawing 1US20190010506A1 — patent drawing 2
View full filing
Most-cited records in scope
#Publication no.Patent titleCitations
1US5508192ABacterial host strains for producing proteolytically sensitive polypeptides845
2US6433252B1Maize L3 oleosin promoter570
3US5514578APolynucleotides encoding insect steroid hormone receptor polypeptides and cells transformed with same310
4US7763420B2Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders246
5WO1996037609A1A gene switch comprising an ecdysone receptor218
6US6245531B1Polynucleotide encoding insect ecdysone receptor210
7US6379945B1Gene switch205
8US6307123B1Methods and compositions for transgene identification130
9US7820184B2Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders126
10US20080193373A1Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders126

Citation counts favour older filings that have had more time to accumulate citations within the searched corpus; treat them as a signal of influence rather than of current commercial weight.

Each row carries its publication number; clicking a row searches Eureka by that number.

Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Engineered Bacteria as Therapeutics covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself

Put your own technology through the same analysis


  
Where to run it
Fastest

Eureka on the web

When you want the answer in the next five minutes.

The agent works the prompt against patents and technical literature, citing every source.

Run your analysis now →
For builders

MCP server & REST API

When it has to run inside your own pipeline.

Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.

Browse MCP servers →
Insights

What the numbers mean for a filing decision

Three patterns stand out once the records are grouped by assignee, technology class and receiving office.

Concentration
50.1%
of records held by top 5

Half the field sits with five assignees

The top 5 assignees hold 565 of the 1,128 records in scope, and the top 10 combined hold 689 (61.1%). That leaves a long tail of single- or few-filing entrants competing for the remaining claim space rather than a broad, even spread of activity.

Based on the full 100-company ranking returned for this dataset.
Momentum
-56%
2021 to 2024 filings

Activity has cooled from its 2020 peak

Filings peaked at 123 in 2020 and declined to 45 by 2024, a 56% drop across the 2021-2024 span. Years beyond 2024 are still incomplete due to publication lag and should not be read as continuing the decline.

2024 is the most recent year treatable as complete.
Class density
82.9%
of records carry C12N

Claims concentrate on strain engineering, not measurement

C12N (microorganisms and genetic engineering) and A61K (medicinal preparations) dominate the corpus at 82.9% and 55.1% of records respectively, while measurement-adjacent classes C12Q and G01N sit at 6.3% and 4.0%. The imbalance suggests analytical and monitoring claims around these strains remain comparatively open.

Shares are of all 1,128 records; a record can carry several classes.
Eureka AI Agent
Looking for what nobody has claimed yet?

Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to engineered bacteria as therapeutics, with the prior art for and against each one.

Find the white space →
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Engineered Bacteria as Therapeutics covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players

Who is filing, and where they overlap

The leader files well ahead of the field, and a small number of institutional pairs account for most of the co-filing activity.

Leader
160
records

One filer sits well clear of the field

The leading assignee holds 160 records against 44 at fifth place and 20 at tenth — a steep drop-off that marks this as a field with one dominant filer rather than several evenly matched ones.

Counted by patent family across the ranked assignees.
Co-filing
136
shared records, strongest pair

Academic-institute pairs anchor co-assignment

Ten co-assignee pairs appear in the dataset. The strongest, an MIT-Broad Institute pairing, spans 136 shared records — far ahead of the next pairs, which sit in the single digits, indicating most collaboration is concentrated in one long-running partnership.

Counts are of shared records between named assignee pairs.
Momentum
-86% to -100%
YoY, latest year

Even active filers are pulling back in the latest year

Several of the more active historical filers show sharp year-on-year declines in the most recent year — MIT down 86%, Broad Institute down 88%, and others at or near zero filings. Given publication lag, this should be read as an incomplete latest year rather than a confirmed pullback.

Momentum figures compare the latest available year to the prior year.
🔍
Under-claimed sub-areas
Branches where filing density is thin relative to the core strain-engineering claims
Kill-switch reliability testing methodsHorizontal gene transfer risk assaysColonization persistence biomarkersInducible expression control circuitsContainment efficiency measurement standards
Rank all filers by momentum →
Recent-year filing momentum by assignee
AssigneeRecent yearYoY
Massachusetts Institute of Technology (MIT)1-86%
The Broad Institute, Inc.1-88%
Synlogic Operating Company, Inc.1-50%
Actym Therapeutics, Inc.0-100%
Synlogic, Inc.0—
Duke University0—
Hervana0—
Yeda Research and Development Co. Ltd.0-100%
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Engineered Bacteria as Therapeutics covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next

Where to take this next

The dataset points to specific next steps depending on whether the goal is freedom-to-operate, portfolio strategy, or spotting open claim space.

Map freedom-to-operate against the top assignees

With half the field held by five assignees, any new filing in strain construction or delivery should be checked against their claim scope before drafting.

Run a freedom-to-operate check in Eureka

Track the collaboration pairs

The MIT-Broad Institute pairing alone spans 136 shared records; watching how such pairs extend their claims signals where the next dense filing cluster will form.

Monitor assignee activity in Eureka

Probe the under-claimed measurement branches

Containment efficiency and horizontal transfer risk assays sit well behind core strain-engineering claims in filing density, suggesting room for a first-mover claim.

Explore white space in Eureka
Source: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Engineered Bacteria as Therapeutics covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ

Common questions on this landscape

Answers are grounded in the same dataset. Derived from a Patsnap search on Engineered Bacteria as Therapeutics covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP

Research Engineered Bacteria as Therapeutics in depth with Eureka

Go past this page: query the whole engineered bacteria as therapeutics corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.

Try Eureka

Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.

Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.

Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.

Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.

Help us improve

Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.